The short version of lipolysis fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-08. Anything still debated is marked as such rather than presented as settled.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
This 1686-amino acid protein belongs to the ADAMTS family and is one of 19 members known in humans. It is a large, multi-domain enzyme that undergoes extensive post-translational modifications, including N- and O-linked glycosylation, chondroitin sulfate attachment, and potential C-mannosylation and O-fucosylation of the thrombospondin (TSP) type 1 domains. The domain structure from the N-terminus to the C-terminus consists of:
The isotopes 192Ir and 60Co are preferred for radiography, since iridium and cobalt are chemically non-reactive metals and can be obtained with much higher specific activities by the activation of stable 191Ir and 59Co in high-flux reactors. However, while 137Cs is a waste product produced in great quantities in nuclear fission reactors, 192Ir and 60Co are specifically produced in commercial and research reactors and their life cycle entails the destruction of the involved high-value elements. Cobalt-60 decays to stable nickel, whereas iridium-192 can decay to either stable osmium or platinum. Due to the residual radioactivity and legal hurdles, the resulting material is not commonly recovered even from "spent" radioactive sources, meaning in essence that the entire mass is "lost" for non-radioactive uses. As an almost purely synthetic isotope not existing in the environment before 1945, caesium-137 has been used to date wine and detect counterfeits and as a relative-dating material for assessing the age of sedimentation occurring after 1945. Caesium-137 is also used as a radioactive tracer in geologic research to measure soil erosion and deposition; its affinity for fine sediments is useful in this application.
A biopharmaceutical, also known as a biological medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, whole blood, blood components, allergenics, somatic cells, gene therapies, tissues, recombinant therapeutic protein, monoclonal antibodies, and living medicines used in cell therapy. Biopharmaceuticals can be composed of sugars, proteins, nucleic acids, or complex combinations of these substances, or may be living cells or tissues. They (or their precursors or components) are isolated from living sources—human, animal, plant, fungal, or microbial. They can be used in both human and animal medicine. Terminology surrounding biopharmaceuticals varies between groups and entities, with different terms referring to different subsets of therapeutics within the general biopharmaceutical category. The term biologics is often used more restrictively to mean biopharmaceuticals that are produced using recombinant DNA technology. Some regulatory agencies use the terms biological medicinal products or therapeutic biological product to refer specifically to engineered macromolecular products like protein- and nucleic acid-based drugs, distinguishing them from products like blood, blood components, or vaccines, which are usually extracted directly from a biological source. Biopharmaceutics is pharmaceutics that works with biopharmaceuticals. Biopharmacology is the branch of pharmacology that studies biopharmaceuticals.
Sources: en.wikipedia.org
Bellido's position on the Camisea gas field was supported by the Free Peru caucus. They denied that this was part of an expropriation campaign, saying that the benefits from resource extraction must be prioritized for Peruvians. The President of Congress, Maricarmen Alva, claimed that Bellido's threats of nationalization generated confusion and would scare away investment. Meanwhile, Vice President Dina Boluarte claimed that Bellido's stance on the Camisea oil field was in line with the President Castillo's views. However, Castillo later stated that any renegotiation of the Camisea gas field contract would be in accordance of the rule of law, and stated that "the State and the private sector work together for a better Peru." Afterward, the Bellido cabinet was removed by the President. Some speculated that Bellido's stance on the Camisea gas field nationalization led to his downfall. However, following the appointment of the Vásquez cabinet, President Castillo urged Congress to make a joint law on the statization or nationalization of the Camisea gas, saying that "It is necessary to give Peruvians what the people have produced." A motion was created in Congress, to ask Prime Minister Mirtha Vásquez to clarify on the President's statements on the Camisea gas fields. On 20 November 2021, the Prime Minister stated that 4 mines in the Ayacucho region would not be allowed any extensions in their operational timelines, and that the mines will be closed as soon as possible on environmental grounds.
Furthermore, a deficiency in GIP receptors has been associated in mice with a dramatic decrease in bone quality and a subsequent increase in fracture risk. However, the results of the two groups' studies were non-concordant.
== Signs and symptoms == Symptoms include catching or locking of the involved finger when it is forcefully flexed (tight fist). There may be tenderness in the palm of the hand near the last skin crease (distal palmar crease). Often a nodule can be felt in this area. There is some evidence that idiopathic trigger finger behaves differently in people with diabetes.
Sources: en.wikipedia.org
== RNA and alternative splicing == The primary transcript of the human RAGE gene (pre-mRNA) is thought to be alternatively spliced. So far about 6 isoforms including the full length transmembrane receptor have been found in different tissues such as lung, kidney, brain etc. Five of these 6 isoforms lack the transmembrane domain and are thus believed to be secreted from cells. Generally these isoforms are referred to as sRAGE (soluble RAGE) or esRAGE (endogenous secretory RAGE). One of the isoforms lacks the V-domain and is thus believed not to be able to bind RAGE ligands.
A polyprotic acid is a compound which may lose more than 1 proton. Stepwise dissociation constants are each defined for the loss of a single proton. The constant for dissociation of the first proton may be denoted as Ka1 and the constants for dissociation of successive protons as Ka2, etc. Phosphoric acid, H3PO4, is an example of a polyprotic acid as it can lose three protons.
==== Oligoarticular arthritis (Oligoarthritis) ==== Oligoarticular (or pauciarticular) JIA is the most common JIA subtype, and occurs when there are up to four joints involved during the first six months of disease. Two subtypes of oligoarticular arthritis exist: persistent oligoarthritis, where no more than four joints are affected throughout the whole disease course; and extended oligoarthritis, where more than four joints are affected after the first six months of disease. Patients in this subtype are often young, typically aged between 1 and 5 years, and are female preponderant. The most commonly involved joint is the knee, but other affected joints may include the ankles, wrists, elbows, and others. 50% of cases involve mono-arthritis, only involving the knee. The anti-nuclear antigen (ANA) is positive in up to 80% of patients with oligoarthritis and is associated with a higher risk of associated eye disease (uveitis), particularly in younger patients. There is no adult counterpart disease to oligoarticular JIA. The prefixes oligo- and pauci- mean 'few'.
Historically, the Wernicke-Kleist-Leonhard school considered periodic catatonia a distinct form of "non-system schizophrenia", characterized by recurrent acute phases with hyperkinetic and akinetic features and often psychotic symptoms. There is also a residual state between these phases, characterized by low-level catatonic features and abulia of varying severity.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.